Drugmaker Novo Nordisk’s CEO Lars Fruergaard Jorgensen came under fire for stating draft legislation requiring greater transparency in pharmaceutical pricing could be bad for business. Jorgensen said draft bills in states, including California and Nevada, would require his company to disclose terms of their contracts, and that would “disclose, basically, how we do business.” The bills originated under pressure from insurers to justify treatment. Novo Nordisk, which continues to specialize in diabetes treatments, had been focused on incrementally modifying the insulin molecule for better results until the Food and Drug Administration deemed Eli Lilly products received preferential treatments due to their lower prices. No longer able to justify the cost of tweaking, Novo Nordisk had to reallocate resources toward discovering disruptive technologies. The company has now branched into researching treatments for diabetes-related diseases, designing experiments to front-load deal killers, and working with a team specializing in navigating FDA approval processes.